Over $100M total capital raised in 2021, providing operational and strategic flexibility to execute mission to broaden patient access to innovative, safe, and efficacious non-hallucinogenic psychoplastogens for the treatment of multiple mental health disorders
Delix Therapeutics, a neuroscience company developing novel disease-modifying therapeutics for psychiatric and neurological conditions, announced that it closed over $30 million in a convertible note financing. Primarily led by existing investors, funding was also provided by select new long-term partners. Additionally, Delix has secured a $10 million Strategic Credit Facility in partnership with Comerica Bank’s Technology & Life Sciences practice, a leading venture debt partner to sponsor-backed businesses. These funds will enhance Delix’s ability to grow its drug development program, pipeline, and platform of novel neuroplasticity-promoting therapeutics known as psychoplastogens; continue to expand its world-class team; and offer the flexibility to execute on additional strategic opportunities in 2022 that support Delix’s mission to become a leading neuroscience company.
“We are fortunate to have built a tremendous investor-syndicate in our $70 million Series A financing round in Q3 2021, while achieving continued growth and operational progress throughout the year. This latest capital raise represents the strength of investor interest, partnership, and support for Delix’s approach to drug development,” said Delix CEO Mark Rus.
Latest Fintech News: New Dawn for SMB Credit Lenders with Uplinq Launch
“Delix has developed a wide-ranging library of novel non-hallucinogenic psychoplastogens, backed by a growing body of scientific data and evidence that demonstrate these compounds’ potentially disease-modifying effects on a variety of brain disorders. We plan to leverage the funds from our growing investor network, and partnership with Comerica, to accelerate the transformation of our scientific discoveries into FDA-approved take-home medicines for a broad set of patients suffering from mental illness or other neurological diseases,” added Rus.
With over thirty years of venture lending experience, Comerica’s Technology & Life Science practice provides customized commercial banking and debt solutions to support rapid business growth. Senior Vice President Bryan Kana, who leads Comerica’s TLS practice in Boston, and Assistant Vice President Lee Eustis underwrote the credit facility on behalf of the bank.
Latest Fintech News: Assent Compliance Announces $350 Million USD Investment to Expand Global Footprint in Supply Chain Sustainability Management
“We focus our life science practice on exceptional management teams, deep scientific platforms, and top-tier equity partners,” said Kana. “Mark and the team at Delix excel across all categories. We’re thrilled to support their growth and the promise they carry for patients fighting neurological diseases and treatment-resistant mental illness.”
In September 2021, Delix Therapeutics closed a $70 million Series A financing round to fund the advancement of its two lead candidates through Phase 1 clinical trials, further expand its drug discovery platform, and rapidly grow its world-class team.
Latest Fintech News: DSS Retains Leading Blockchain and Digital Assets Law Firm to Accelerate Launch of Digital Asset Exchange
[To share your insights with us, please write to sghosh@martechseries.com]
